Target product profile for schistosomiasis

Schistosomiasis

Target product profile for schistosomiasis

DNDi aims to develop a single-dose oral treatment for schistosomiasis that is active against both adult and juvenile worms across all Schistosoma species and that is suitable for all ages and for women who are or may become pregnant.

	Ideal	Acceptable
Formulation	Oral, palatable Children: specific tablet or oral suspension for young children	Oral, palatable Children: safe for use from 2 years of age
Target species	Active against S. mansoni and S. haematobium and all Schistosoma species	Active against at least S. mansoni and S. haematobium
Target population	All people at risk of schistosomiasis	People infected with schistosomiasis, except for pregnant women and children younger than 2 years
Treatment regimen	Single dose, one dose for all ages	Oral dose once or twice a day for up to 3 days One dose for adults and weight-, age-, or height-adjusted dosing for children
Efficacy	High efficacy against all stages of the worm life cycle in human hosts and some measure of protection against reinfection	High efficacy against adult worms; efficacy against other life cycle stages
Safety/tolerability	No adverse effects, precautions, or population restricted use at registration	Minor/manageable side effects, monitoring manageable and primary healthcare level, restriction only for women who are pregnant or breastfeeding and people who are acutely ill
Drug-drug interactions	No clinically significant interactions with other anti-parasitic or anti-infective drugs or chronic medications	Manageable for individual case management
Stability	More than 2 years in climatic zone IVb	2 years in climatic zone IVb

Making medical history for neglected patients

We develop urgently needed treatments for neglected patients and ensure they’re affordable, available, and adapted to the communities who need them

Chagas disease

Causes heart and vital organ damage, after people are bitten by blood-sucking bugs

We delivered the first-ever treatment for children; now we’re searching for new drug candidates and working to boost access to care

Cryptococcal meningitis

Without treatment, deadly for thousands of people with advanced HIV

We’re working to improve access to life-saving treatments and developing an easier-to-use formulation

Cutaneous leishmaniasis

Leaves disfiguring, life-long scars that lead to severe social stigma

We’re working to develop safer, shorter treatments for this disabling disease

Dengue

Rapidly spreading climate-sensitive disease with no specific treatment

We’re building a global partnership with dengue-endemic countries to develop a first treatment

Hepatitis C

Millions are left without treatment even though effective drugs exist

We’ve delivered a treatment as simple, safe, and effective as the best drugs available today – at a fraction of the cost

Mycetoma

Often ends in amputation, after people get infected from stepping on a thorn

We conducted the world’s first trial for an alternative to current treatments, which are toxic and difficult to administer

Paediatric HIV

Without treatment, half of children die before their second birthday

We’ve developed a strawberry-flavoured treatment to meet the needs of children long neglected by the global HIV response

Pandemic Preparedness

The COVID-19 pandemic intensified global health inequalities

We’re bringing together partners and accelerating research to prepare for future viral pandemics in low-resource settings

Parasitic worms

Cause debilitating illness, social exclusion, and long-term disability

We’re working across multiple diseases to develop missing cures that can prevent lasting harm

Sleeping sickness

Transmitted by the bite of a tsetse fly and causes severe neurological disorders

We delivered a revolutionary new drug to replace toxic treatments, and have ongoing trials to eliminate this disease